Abstract
The enzyme human aromatase (HA), a member of the cytochrome P450 family, catalyses in a highly specific and peculiar manner the conversion of estrogens to androgens. Thus, this enzyme is a relevant target for inhibitor design for the treatment of breast cancer and currently there are several HA inhibitors employed in clinical practice. The HA crystal structure was solved only in 2009 and, since then, several studies have been done to characterize a variety of its structural, dynamical and mechanistic properties. In the last decade, the predictive power and the accuracy of computer simulations techniques, either relying on force field or on “ab initio” description of the system, has enormously increased. This was mainly due to the development of more accurate algorithms, which allow accelerating the time-scale accessible by simulations techniques, and to the increase of computer power. Hence, computer simulations can now accurately paint an atomistic picture to the molecular mechanism of biomolecules providing also an estimate of the kinetic and thermodynamic properties of the enzyme at increasingly quantitative level. In this review, on the basis of selected examples taken from our work, we summarize current active research topics concerning HA enzyme, with a focus on computational studies. In particular, we will illustrate current results and novel hypothesis concerning the final (rate-determining) aromatization step promoted by this enzyme, on how the structural/dynamics/functional properties of HA are modulated in a membrane lipophilic environment, and finally on novel possible (allosteric) inhibition mechanisms which may modulate estrogen production in HA.
Keywords: Allosteric site, Drug design, Enzymatic, Human Aromatase, Inhibition mechanism, Ligand binding, Molecular dynamics, P450, QM/MM.
Mini-Reviews in Medicinal Chemistry
Title:Enzymatic and Inhibition Mechanism of Human Aromatase (CYP19A1) Enzyme. A Computational Perspective from QM/MM and Classical Molecular Dynamics Simulations
Volume: 16 Issue: 14
Author(s): Jacopo Sgrignani, Andrea Cavalli, Giorgio Colombo and Alessandra Magistrato
Affiliation:
Keywords: Allosteric site, Drug design, Enzymatic, Human Aromatase, Inhibition mechanism, Ligand binding, Molecular dynamics, P450, QM/MM.
Abstract: The enzyme human aromatase (HA), a member of the cytochrome P450 family, catalyses in a highly specific and peculiar manner the conversion of estrogens to androgens. Thus, this enzyme is a relevant target for inhibitor design for the treatment of breast cancer and currently there are several HA inhibitors employed in clinical practice. The HA crystal structure was solved only in 2009 and, since then, several studies have been done to characterize a variety of its structural, dynamical and mechanistic properties. In the last decade, the predictive power and the accuracy of computer simulations techniques, either relying on force field or on “ab initio” description of the system, has enormously increased. This was mainly due to the development of more accurate algorithms, which allow accelerating the time-scale accessible by simulations techniques, and to the increase of computer power. Hence, computer simulations can now accurately paint an atomistic picture to the molecular mechanism of biomolecules providing also an estimate of the kinetic and thermodynamic properties of the enzyme at increasingly quantitative level. In this review, on the basis of selected examples taken from our work, we summarize current active research topics concerning HA enzyme, with a focus on computational studies. In particular, we will illustrate current results and novel hypothesis concerning the final (rate-determining) aromatization step promoted by this enzyme, on how the structural/dynamics/functional properties of HA are modulated in a membrane lipophilic environment, and finally on novel possible (allosteric) inhibition mechanisms which may modulate estrogen production in HA.
Export Options
About this article
Cite this article as:
Sgrignani Jacopo, Cavalli Andrea, Colombo Giorgio and Magistrato Alessandra, Enzymatic and Inhibition Mechanism of Human Aromatase (CYP19A1) Enzyme. A Computational Perspective from QM/MM and Classical Molecular Dynamics Simulations, Mini-Reviews in Medicinal Chemistry 2016; 16 (14) . https://dx.doi.org/10.2174/1389557516666160623101129
DOI https://dx.doi.org/10.2174/1389557516666160623101129 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis of [DTPA-bis(D-ser)] Chelate (DBDSC): An Approach for the Design of SPECT Radiopharmaceuticals Based on Technetium
Current Radiopharmaceuticals Production of Retroviral Vectors: Review
Current Gene Therapy West Nile Virus NS2B/NS3 Protease As An Antiviral Target
Current Medicinal Chemistry QSAR Multi-Target in Drug Discovery: A Review
Current Computer-Aided Drug Design A Critical Review on the Unexplored Therapeutic Treasure of Himalayan Ayurvedic Drug Daruharidra (<i>Berberis Aristata</i>)
Current Traditional Medicine Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Review of Chemoradiotherapy for High-Risk Prostate Cancer
Reviews on Recent Clinical Trials Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy CPP-Based Bioactive Drug Delivery to Penetrate the Blood-Brain Barrier: A Potential Therapy for Glioblastoma Multiforme
Current Drug Targets Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy
Current Pharmaceutical Design Estrogen Receptor Modulators: Relationships of Ligand Structure, Receptor Affinity and Functional Activity
Current Topics in Medicinal Chemistry TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta
Current Molecular Medicine Iodine in Mammary and Prostate Pathologies
Current Chemical Biology Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Discovery of New Biomarkers of Cancer Using Proteomics Technology
Current Cancer Therapy Reviews Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology